Kaplan/First Aid Pharm Flashcards
bleomycin is cell-cycle specific to which phase (S/G2/M/G1/G0)
G2
vinblastine, vincristine, paclitaxel are cell-cycle specific to which phase (S/G2/M/G1/G0)
M
cytarabine, 6-mercaptopurine, 5-fluorouracil, methotrexate, hydroxyurea, irinotecan, etoposide are cell-cycle specific to which phase (S/G2/M/G1/G0)
S
alkylating agents (cyclophosphamide, cisplatin, procarbazine), antitumor antibiotics (doxorubicin, daunorubicin), nitrosoureas (lomustine, carmustine) are cell-cycle specific to which phase (S/G2/M/G1/G0)
SYKE they are non cell cycle specific
log-kill hypothesis of cancer drugs: cytotoxic actions of anticancer drugs kill a fixed (number/percentage) of tumor cells
PERCENTAGE (one rationale for drug combinations)
drugs that are cell cycle specific are more effective in tumors with (high/low) growth fraction
high (leukemias, lymphomas)
drugs that are cell cycle nonspecific are more effective in tumors with (high/low) growth fraction
can be used for either
used to relieve hemorrhagic cystitis side effect from cyclophosphamide: (amifostine/mesna/leucovorin)
mesna
used to relieve nephrotoxicity side effect from cisplatin: (amifostine/mesna/leucovorin)
amifostine
used to relieve bone marrow suppression side effect from methotrexate: (amifostine/mesna/leucovorin)
leucovorin
used to relieve delayed CHF side effect from doxorubicin: (amifostine/mesna/dexrazoxane/leucovorin)
dexrazoxane
dose-limiting toxicity for cisplatin, methotrexate: (pulmonary/renal/neuro/cardiac/immunosuppressive)
renal
dose-limiting toxicity for bleomycin, procarbazine: (pulmonary/renal/neuro/cardiac/immunosuppressive)
pulmonary
dose-limiting toxicity for doxorubicin, daunorubicin: (pulmonary/renal/neuro/cardiac/immunosuppressive)
cardiac
dose-limiting toxicity for vincristine, cisplatin: (pulmonary/renal/neuro/cardiac/immunosuppressive)
neuro
dose-limiting toxicity for cyclophosphamide, methotrexate: (pulmonary/renal/neuro/cardiac/immunosuppressive)
immunosuppressive
dose limiting side effect for cyclophosphamide other than immunosuppression that can be relieved by mesna
hemorrhagic cystitis
dose limiting side effect for procarbazine that is a real bummer
leukemia
(cyclophosphamide/cisplatin/procarbazine/doxorubicin): alkylating agent that attacks guanine N7–dysfunctional DNA
cyclophosphamide
(cyclophosphamide/cisplatin/procarbazine/doxorubicin): alkylating agent–cross links DNA strands
cisplatin
(cyclophosphamide/cisplatin/procarbazine/doxorubicin): intercalator, forms free radicals, inhibits topoisomerase
doxorubicin
(cyclophosphamide/cisplatin/procarbazine/doxorubicin): alkylating agent for treatment of Hodgkin
procarbazine
(methotrexate/5-fluorouracil and Capecitabine/6-mercaptopurine/bleomycin): antimetabolite–inhibits DHF reductase
methotrexate
(methotrexate/5-fluorouracil and Capecitabine/6-mercaptopurine/bleomycin): pyrimidine antimetabolite, bioactivated to inhibit thymidylate synthetase
5-fluorouracil and capecitabine (oral)
(methotrexate/5-fluorouracil and Capecitabine/6-mercaptopurine/bleomycin): purine antimetabolite, bioactivated by HGPR transferase
6-mercaptopurine
(methotrexate/5-fluorouracil and Capecitabine/6-mercaptopurine/bleomycin): complexes with Fe and O2, DNA strand scission
bleomycin
(vinblastine and vincristine/all-trans retinoic acid ATRA): decreases microtubular polymerization–spindle poisons
vinblastine and vincristine
(vinblastine and vincristine/all-trans retinoic acid ATRA): differentiating agent, promotes differentiation of promyelocytes
ATRA
thymineless death of neoplastic cells accomplished by bioactivation of (methotrexate/5-fluorouracil and Capecitabine/6-mercaptopurine/bleomycin) to inhibit thymidylate synthetase
5-fluorouracil